コンテンツへスキップ
Merck

SML2022

Sigma-Aldrich

UCSF924

≥98% (HPLC)

別名:

6-Methyl-2-((3-phenoxypropylamino)methyl)quinolin-4(1H)-one, ZINC000091726127

ログイン組織・契約価格を表示する


About This Item

実験式(ヒル表記法):
C20H22N2O2
CAS番号:
分子量:
322.40
UNSPSCコード:
12352200
NACRES:
NA.77

アッセイ

≥98% (HPLC)

フォーム

powder

white to beige

溶解性

DMSO: 2 mg/mL, clear

保管温度

−20°C

SMILES記法

CC1=CC=C(NC(CNCCCOC2=CC=CC=C2)=CC3=O)C3=C1

関連するカテゴリー

生物化学的/生理学的作用

Selective, high-affinity dopamine D4 receptor (DRD4) partial agonist with a 7.4-fold bias toward arrestin recruitment over Gα signaling with respect to quinpirole.
UCSF924 (Compound 9-6-24; ZINC000091726127) is a selective, high-affinity dopamine D4 receptor (DRD4) partial agonist (Ki = 3 nM for human D4) with a 7.4-fold bias toward arrestin recruitment over Gαi (Gαi/0; Gi/G0) signaling activation with respect to quinpirole. UCSF924 exhibits no detectable affinity for D2, D3 or the F261V/L328F D4 mutant and no agonist activity toward a panel of 320 nonolfactory GPCRs even at a high concentration of 1 μM. The UCSF924 structure analog UCSF924NC (Comound 9-6-16; ZINC000091707446) is the recommended negative control compound with a 1/2500-fold reduced D4 affinity.

保管分類コード

11 - Combustible Solids

WGK

WGK 3

引火点(°F)

Not applicable

引火点(℃)

Not applicable


適用法令

試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。

Jan Code

SML2022-5MG:
SML2022-BULK:
SML2022-VAR:
SML2022-25MG:


最新バージョンのいずれかを選択してください:

試験成績書(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 資料 section.

サポートが必要な場合は、お問い合わせください カスタマーサポート

以前この製品を購入いただいたことがある場合

文書ライブラリで、最近購入した製品の文書を検索できます。

文書ライブラリにアクセスする

Xiaocong M Ye et al.
Bioorganic & medicinal chemistry letters, 23(4), 996-1000 (2013-01-15)
Structure-activity relationship (SAR) of a novel, potent and metabolically stable series of benzo [3.2.1] bicyclic sulfonamide-pyrazoles as γ-secretase inhibitors are described. Compounds that are efficacious in reducing the cortical Aβx-40 levels in FVB mice via oral dose, as well as
Dolores Del Prete et al.
Journal of Alzheimer's disease : JAD, 55(4), 1549-1570 (2016-12-03)
Alteration of mitochondria-associated membranes (MAMs) has been proposed to contribute to the pathogenesis of Alzheimer's disease (AD). We studied herein the subcellular distribution, the processing, and the protein interactome of the amyloid-β protein precursor (AβPP) and its proteolytic products in
Inger Lauritzen et al.
The Journal of neuroscience : the official journal of the Society for Neuroscience, 32(46), 16243-1655a-16243-1655a (2012-11-16)
Triple-transgenic mice (3xTgAD) overexpressing Swedish-mutated β-amyloid precursor protein (βAPP(swe)), P310L-Tau (Tau(P301L)), and physiological levels of M146V-presenilin-1 (PS1(M146V)) display extracellular amyloid-β peptides (Aβ) deposits and Tau tangles. More disputed is the observation that these mice accumulate intraneuronal Aβ that has been
Rampurna Gullapalli et al.
Drug delivery, 19(5), 239-246 (2012-06-05)
Hydrophilic, non-aqueous solvents are frequently used to solubilize poorly water soluble compounds for use in ALZET® osmotic pumps used during the discovery and preclinical stages. Though these solvents exhibit the potential to solubilize several poorly soluble compounds, the solubilized compounds
Kevin Quinn et al.
Journal of pharmaceutical sciences, 101(4), 1462-1474 (2012-01-04)
ELND006 is a novel gamma secretase inhibitor previously under investigation for the oral treatment of Alzheimer's disease. ELND006 shows poor solubility and has moderate to high permeability, suggesting it is a Biopharmaceutics Classification System Class II compound. The poor absolute

ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.

製品に関するお問い合わせはこちら(テクニカルサービス)